Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-12-10 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于召开2019年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2019 first extraordinary general meeting (临时股东大会) of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items including board and supervisory committee elections, amendments to company articles, and other shareholder proposals. It also contains attachments such as proxy forms and shareholder registration forms. The content is focused on informing shareholders about the meeting logistics and agenda, not the results of the voting or the meeting itself. This type of document is a meeting notice or announcement rather than the actual voting results or minutes. Therefore, it fits best into the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is sufficient and contains substantive meeting details, not just a brief announcement or a regulatory filing. Hence, the classification is AGM-R with high confidence.
2019-12-10 Chinese
股东大会议事规则（2019年12月）
Governance Information Classification · 95% confidence The document is titled as the "Shareholders' Meeting Rules" of 安徽安科生物工程（集团）股份有限公司 dated December 2019. It details the procedures, rights, and responsibilities related to the company's shareholders' meetings, including the convening, notification, proposal submission, voting, and record-keeping processes. It does not contain financial statements, earnings data, or audit information. It is a governance-related document outlining internal rules and procedures for shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not an RPA or RNS.
2019-12-10 Chinese
公司章程修正案（2019年12月）
Governance Information Classification · 95% confidence The document is titled as a "Company Articles of Association Amendment" (公司章程修正案) dated December 2019. It details specific revisions to the company's articles of association, including changes in terminology from general manager to president, adjustments in board and management roles, and procedural updates. The content is focused on governance structure and internal rules rather than financial data or operational results. The document is relatively short (4081 characters) and does not contain financial statements or performance data. It is not an announcement of a report but the actual amendment text to the company's governance documents. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2019-12-10 Chinese
独立董事提名人声明（三）
Board/Management Information Classification · 100% confidence The document is a formal statement nominating an individual as an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically the nomination of a board member. The document length is under 5,000 characters and does not indicate it is an announcement of a report publication or a certification. Therefore, the document fits best under the category of Board/Management Information (MANG).
2019-12-10 Chinese
独立董事候选人声明（刘光福）
Regulatory Filings Classification · 95% confidence The document is a formal declaration by an independent director candidate, Liu Guangfu, for Anhui Anke Biotechnology (Group) Co., Ltd. It contains detailed statements confirming compliance with various legal and regulatory requirements for serving as an independent director. There are no financial statements, earnings data, or report summaries. The content focuses on governance and compliance related to board membership qualifications. It is not an annual report, earnings release, or any financial report. It is also not a voting result or proxy solicitation. The document is a regulatory filing related to board governance and director qualifications, but it is not announcing a change in management or board members. Given the nature of the document as a formal declaration of director independence and qualifications, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2019-12-10 Chinese
独立董事关于公司第六届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on the nomination and election of board members for the company's seventh board of directors. It discusses compliance with laws and regulations regarding board nominations and the qualifications of candidates. There is no financial data, earnings information, or report publication mentioned. The content focuses on board and management changes and governance matters. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and does not indicate it is a report or announcement of a report, so it is not RPA or RNS.
2019-12-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.